Nutu™ Digital Health Platform for Obesity

DS
Overseen ByDrew Sayer, PhD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: University of Alabama at Birmingham
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This study evaluates the acceptability and clinical effectiveness of integrating the Nutu™ digital health platform into a comprehensive primary care-based behavioral obesity treatment program using a Zelen randomized controlled trial design.

Who Is on the Research Team?

DS

Drew Sayer, PhD

Principal Investigator

University of Alabama at Birmingham

Are You a Good Fit for This Trial?

Inclusion Criteria

All patients enrolled in the FLOW clinical program are eligible.

Exclusion Criteria

Not a patient of the FLOW clinical program at UAB.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive the standard 12-month FLOW program, with or without the Nutu™ digital health platform

12 months
Quarterly visits

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Nutu™

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Active Control

Group I: FLOW + Nutu™ OfferExperimental Treatment2 Interventions
Group II: Standard FLOW ProgramActive Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Alabama at Birmingham

Lead Sponsor

Trials
1,677
Recruited
2,458,000+

Willow Laboratories, Inc.

Collaborator